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We developed a method based on liquid chromatography coupled
with tandem mass spectrometry to quantify individual enantiomers
of methadone and its primary metabolite, R/S-2-ethyl-1,5-dimethyl-
3,3-diphenylpyrrolinium (EDDP), in postmortem blood and brain
tissue. Samples were prepared with a Tecan Evo robotic system.
Precipitation was followed by solid-phase extraction, evaporation
and reconstitution in the mobile phase. Enantiomers were fully
separated with liquid chromatography on a chiral a(1)-acid glyco-
protein column. A Quattro micro mass spectrometer was used for
detection in the positive ion mode with an electrospray source. The
lower limit of quantification in brain tissue was 0.005 mg/kg for
methadone and 0.001 mg/kg for EDDP enantiomers; the maximum
precision was 17% for both compounds; accuracy ranged from 94
to 101%. In blood, the limit of quantification was 0.001 mg/kg for
all compounds, the total relative standard deviation was <15%, and
the accuracy varied from 95 to 109%. Brain (n 5 11) and blood
(n 5 15) samples were analyzed with intermediate precision that
varied from 7.5 to 15% at 0.005 mg/kg and from 6.8 to 11.3% at
0.25 mg/kg for all compounds. Method development focused on
producing a clean extract, particularly from brain samples. The
method was tested on authentic brain and femoral blood samples.
Introduction
Methadone is the primary drug used in maintenance treatment
of individuals with drug dependence in Denmark; in addition, it
is the most common cause of death in poisoning cases among
drug addicts (1, 2). Methadone has increasingly been used as a
chronic pain medication, and fatal poisonings have also occurred
in that context (3). In most countries, methadone is adminis-
tered as a racemic mixture of R- and S-enantiomers, but the
R-form is responsible for the major part of the drug effect (4–6).
Methadone provides analgesic and euphoric effects by stimu-
lating the m- and d-opioid receptors in the central nervous
system (4). It is excreted by the kidneys, and it is primarily
metabolized to the inactive metabolite, R/S-2-ethyl-1,5-dimethyl-3,
3-diphenylpyrrolinium (EDDP), which is observed in consider-
ably lower concentrations than methadone in blood (7, 8).
Recent studies have described methods for chiral separation of
the two enantiomers (9–23); however, methadone is commonly
measured with achiral methods in routine settings. A variety of
methods have also been published for measuring methadone and
EDDP in various types of media, including adipose matrices, brain
tissue, breast milk and larva (24–26); however, to our knowledge,
only one of those methods separated the enantiomers (24).
The active form of methadone can be identiﬁed and quanti-
ﬁed in the target organ by analyzing brain samples. The pro-
tected position of the brain and its low metabolic activity may
delay postmortem putrefaction and decomposition processes.
Thus, the brain matrix offers an advantage over other post-
mortem specimens (27, 28), because postmortem and perimor-
tem methadone concentrations in brain may be less inﬂuenced
by the time between death and analysis than methadone con-
centrations in other tissue types.
We previously developed a chiral method for quantifying
methadone in postmortem blood samples based on liquid–
liquid extraction (29). Attempts to apply this method to brain
samples resulted in large variations in retention time (Rt) on the
a(1)-acid glycoprotein (AGP) chiral column over a limited
number of injections, and restitution of the column required a
long ﬂushing time. The aim of this work was to produce a reli-
able chiral method for quantifying both methadone and the me-
tabolite, which may occur in low concentrations. We focused
on the development of a solid-phase extraction (SPE) procedure
that provided clean extracts to ensure stable chromatography.
Apparatus
Sample preparation, including SPE, was automatically performed
on a Tecan Freedom Evo 150 robotic platform (Tecan,
Ma¨nnedorf, Switzerland) equipped with the following modules: a
Tecan liquid handling arm with eight independent pipetting
channels that used disposable ﬁlter tips; a Tecan robot manipula-
tor arm for plate movements, a Tecan Te-Vacs vacuum station for
SPE; a Tecan Te-Shake orbital plateshaker, a Mettler Toledo
XP203S balance for weighing samples (Mettler Toledo,
Switzerland), a Porvair Ultravap evaporator (Norfolk, UK), and a
FluidX Xat-384 automated thermal sealer (Cheshire, UK). All
modules were programmed and controlled with Tecan Evoware
2.3 SP3. The platform setup was similar to that presented by
Andersen et al. (30), with a few modiﬁcations due to a difference
in the size of the platform. The platform used during validation
was a 150-cm model, and therefore, it did not include an
on-system centrifuge; instead, a Centrifuge 5804 R (Eppendorf,
Hamburg, Germany) was used. The SPE column was a Strata-X-C
33u polymeric strong cation 96-well plate with 30 mg/well
(Phenomenex, Torrance, CA). Before analysis, brain samples
were homogenized on a Gentlemacs Dissociator from Miltenyi
Biotec (Bergisch Gladbach, Germany).
A chiral AGP guard column (10  4.0 mm i.d., 5 mm) and a
chiral AGP analytical column (100  4.0 mm i.d., 5 mm) from
Supelco (Bellefonte, PA) were used in series for separation on
the liquid chromatography (LC) system. The LC system con-
sisted of an 1100 series high-performance liquid chromatog-
raphy (HPLC) system from Agilent Technologies (Waldbronn,
Germany). It was equipped with a binary pump, an auto
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sampler and a temperature-regulated column compartment. A
Quattro micro (tandem quadruple mass spectrometer, MS-MS)
from Waters (Manchester, UK) was coupled to the HPLC
system. Data were acquired in the positive ion mode with an
electrospray ionization (ESI) source using MassLynx software
4.1. Quantiﬁcation was based on ion chromatograms extracted
with QuanLynx.
Chemicals
Racemic (rac) mixtures of rac-methadone (HCl salt, 99.99%),
rac-EDDP (HClO4 salt, 99.99%), and rac-EDDP-D3 (ClO4 salt,
99%) were purchased from Lipomed (Arlesheim, Switzerland);
rac-methadone-D3 (99%) was obtained from Cerilliant (Round
Rock, TX). R-methadone (HCl salt, 99.9%) was acquired from
Sanoﬁ-Aventis (Frankfurt, Germany). Organic solvents were
HPLC or liquid chromatography–mass spectrometry (LC–MS)
grade from Fischer (Leicestershire, UK), and formic acid
(98%) was from Sigma-Aldrich (Steinheim, Germany).
Analytic-grade hydrochloric acid (fuming 37%), ammonium
solvent (25%), ammonium acetate, potassium dihydrogenpho-
sphate, and sodium hydroxide were purchased from Merck
(Damstadt, Germany). All experiments included water that was
puriﬁed with the Millipore Synergy UV water puriﬁcation
system (Millipore A/S, Copenhagen, Denmark).
Distinguishing between R- and S-enantiomers of EDDP was
performed by injecting R-methadone extracts treated with the
relevant enzyme to produce a detectable amount of R-EDDP
(17). These enzymes included baculovirus-infected insect cell
microsomes containing the cDNA-expressed P450 CYP isoen-
zymes (2B6, 2D6 and 3A4), UltraPool human liver microsomes
(HLM) 150, pooled human liver S9, and NADPH regeneration
system solutions A and B, all purchased from BD Biosciences
(Woburn, MA).
Controls and standards
We prepared standard stock solutions of 1 mg/mL rac-
methadone in methanol (MeOH), 1 mg/mL rac-EDDP in
MeOH, 0.1 mg/mL methadone-D3 in MeOH and 0.1 mg/mL
EDDP-D3 in MeOH. A mixed calibration standard solution of
5 mg/L R-methadone, S-methadone, R-EDDP and S-EDDP was
made by diluting the stock solution with 50:50 v/v MeOH–
water. The internal standard (IS) work solution was prepared
in 50:50 v/v MeOH–water. This was used to dilute the stock
solutions described previously to a 0.5 mg/L concentration of
each methadone-D3 and EDDP-D3 enantiomer.
Control blood samples were prepared with blood obtained
from the local blood bank. Control brain samples were pre-
pared with a pooled brain homogenate of both grey and white
matter from negative samples. Blood and brain quality controls
(QC) were prepared by spiking a known mass of sample into
low (0.005 mg/kg) and high (0.25 mg/kg) levels of each
methadone and EDDP enantiomer. QC samples were stored at
2808C. Control samples were included in every run.
Method development
During the method development phase, the two primary prior-
ities were to achieve a highly clean ﬁnal extract (to enable stable
chromatography) and the highest possible recovery of EDDP
(EDDP concentrations tend to be low in authentic samples).
First, we precipitated with MeOH, acetonitrile (ACN)–H2O,
and ACN, then we tested extracting with phosphate buffer
(0.1M, pH 6), with or without SPE. We also tested the buffer
extraction with a precipitation step after reconstitution with
hexane. The precipitation quality was evaluated based on the
clarity of the supernatant after centrifugation and the degree of
ion suppression during injection of the ﬁnal reconstituted
extracts. The general extent of ion suppression was examined
on a C18 column. This allowed the application of an organic
phase gradient up to 100% (data not shown). We investigated
ion suppression separately in the ﬁnal analysis on the chiral
column.
Recovery of methadone and EDDP was compared on differ-
ent SPE columns (HLB, HCX and Strata-X-C). We tested differ-
ent organic solvents to wash the SPE column, including MeOH,
ACN, 50:50 v/v ACN–H2O and 80:20 v/v toluene–ethylacetate.
The quality of each wash was evaluated based on the loss of
analytes and the peak signals measured at 184. 184 m/z and
104. 104 m/z, which are commonly used to measure phos-
pholipids (31).
The release of analytes from the SPE column was examined
with two different elution solvents, including 5%, 25%
NH3-solution in MeOH (MeOH–NH3, suggested by the manu-
facturer) and a 4%, 25% NH3-solution in ACN (ACN–NH3). The
SPE columns were loaded with analyte-fortiﬁed brain ACN
supernatants and eluted in singles with volumes of 100, 200,
300, 400, 500, 600, 700 and 900 mL MeOH–NH3 or ACN–NH3,
respectively; IS was added before evaporation. The analyte pro-
ﬁles at each volume of eluate were used as an expression of
recovery.
For LC separation of the compounds, we used a gradient of
2-propanol in 15 mM ammonium acetate buffer with 0.01%
formic acid (pH 5.3).
Validation
The LC–MS-MS method was validated according to Peters et al.
(32) and in-house procedures. The validation parameters
included selectivity, ion suppression, matrix effect, recovery,
extract stability, linearity, limit of detection (LOD), lower
limit of quantiﬁcation (LLOQ), higher limit of quantiﬁcation
(HLOQ), accuracy, precision and carry-over.
Selectivity was examined by injecting 2 mg/L of standard
solutions that contained acetyl-methadol, nicotine, caffeine,
tetrahydrocannabinol (THC), THC-acid, 62 other common
drugs of abuse, benzodiazepines and metabolites, basic drugs
and metabolites, acidic or neutral drugs, and the methadone
metabolites, nor-methadone and R/S-2-ethyl-5-methyl-3,3-
diphenylpyrroline (EDMP). The examined drugs are listed in
Table I.
Ion suppression was examined by constantly injecting ana-
lytes through a T-piece at 0.1 ng/min, and simultaneously
injecting various extracts from negative cases or solutions with
co-eluting drugs. Extracts from femoral blood (n ¼ 5), white
brain matter (n ¼ 1), grey brain matter (n ¼ 1), a mixture of
white and grey brain matter (n ¼ 6) and a blank mobile phase
were injected together with a standard that contained the four
compounds of interest. Matrix effects were examined by ﬁrst
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evaluating the peak area of extracts that had been fortiﬁed
with analyte (0.04 mg/L) after extraction and then comparing
with the peak areas of injected pure standards. Seven brain
extracts and eight blood extracts were examined. Extraction re-
coveries were determined by comparing peak areas of samples
fortiﬁed before and after the precipitation and SPE steps.
The linearity of the four compounds in brain tissue was eval-
uated based on seven levels of fortiﬁcation (ranging from
0.0005–2.00 mg/kg) in brain homogenates, each level per-
formed in triplicate, nine levels of fortiﬁcation (ranging from
0.0001–2.00 mg/kg) in blood performed in triplicate, and
blanks.
Accuracy, precision, LLOQ and HLOQ were assessed on the
basis of quadruple determinations of seven fortiﬁed blood
samples (ranging from 0.0005–2.0 mg/kg) and six fortiﬁed
brain samples (ranging from 0.001–2.0 mg/kg) performed on
three different days. The controls were fortiﬁed as a pool, por-
tioned out, and stored at –808C until analysis.
Final analytical procedure
Sample preparation
Samples were postmortem femoral blood and frontal lobe brain
tissue obtained from an autopsy. Femoral blood samples were
stabilized with 10 mg sodium ﬂuoride.
For brain analysis, 2–4 g of grey matter was obtained from a
frontal lobe sample that had been stored at –208C between
autopsy and sampling. The grey matter was homogenized un-
diluted at room temperature and stored at –808C in aliquots of
0.5–1 g until analysis. Calibration samples based on triple mea-
surements of a blank matrix and 0.5 mg/kg of a matrix fortiﬁed
with each enantiomer was included in each run. With a posi-
tive displacement pipette, brain samples were transferred
manually to a scale and weights were recorded. For blood
samples, 200 mL of each sample was weighed during automated
transfer to a 2-mL, 96-well plate placed on the balance; the
weights were recorded automatically. A volume of 20 mL IS so-
lution was added to each well, followed by precipitation of the
samples with 900 mL ACN added slowly over 3 min during
orbital shaking of the plate. The plate was centrifuged for
5 min at 3,600 rpm, while the SPE columns were precondi-
tioned and equilibrated with 900 mL MeOH and 900 mL water.
After centrifugation, 900 mL supernatant was transferred to the
preconditioned SPE columns together with 100 mL 0.1M phos-
phate buffer (adjusted to pH 6 with NaOH). Columns were
consecutively washed with 900 mL 0.1M HCl solution, 2 
900 mL MeOH, and 100 mL freshly prepared ACN containing 4%
v/v 25% NH3 solution. Next, 20 mL 2% formic acid in water was
added to the collection wells, followed by elution with 400 mL
freshly prepared ACN containing 4% v/v 25% NH3 solution.
The eluate was evaporated to dryness with 358C N2 and recon-
stituted with 3 min of orbital shaking in 100 mL mobile phase
(MP, 20% 2-propanol in 15 mM ammonium acetate, 0.01%
formic acid, pH 5.3).
LC–MS-MS analysis
A gradient of 2-propanol and freshly prepared 15 mM ammo-
nium acetate buffer with 0.01% formic acid (pH 5.3) was
applied to the column for complete separation of the metha-
done and EDDP enantiomers (Table II). The gradient started
with 5% 2-propanol for 7.5 min, followed by an increase to 12%
over 1 min, and then it was held at 12% for 4.5 min before
implementing a rapid increase to 20% over 0.1 min; then, the
20% 2-propanol was held until reaching a total run time of
19 min; next, the gradient was decreased over 0.1 min to 5%;
after 26 min, the system was fully stabilized and ready for a
new injection. The ﬂow was set to 0.400 mL/min, and 10 mL of
reconstituted eluate was injected into the LC–MS-MS system.
The column temperature was 258C. MS conditions were opti-
mized by running a large variety of cone and collision energies
during the injection of a system control. We selected the
Table II
Gradient Used on the LC–MS-MS System*
Time (min) A (%)
0.0 5
7.5 5
8.5 12
13.0 12
13.1† 20
19.0 20
19.1 5
26.0 5
*Note: Solvent A, 2-propanol; solvent B, 15 mM ammonium acetate with 0.01% formic acid
(pH ¼ 5.3).
†This gradient step has a rinsing function necessary during brain sample injection.
Table I
Drugs and Metabolites Examined for Interference During the Selectivity Experiment, Listed
Alphabetically
6-Monoacetylmorphine Methadone, nor-
3,4-Methylenedioxyamphetamine Methamphetamine
3,4-Methylenedioxymethamphetamine Methotrimeprazine
Alprazolam Methylenedioxyethylamphetamine
Amitrophtyline Methylphenidate
amphetamine Metoclopramide
Benzoylecgonine Metoprolol
Bromazepam Mianserine
Buprenorphine Mirtazapine
Buprenorphine, nor- Morphine
Caffeine Nicotine
Chlordiazepoxide Nitrazepam
Chlorprothixen Nitrazepam, 7-amino
Chlorprothixen, dem- Norfluoxetine
Citalopam, dem- Nortriptyline
Citalopram Orphenadrine
Clonazepam Orphenadrine, dem-
Clonazepam, 7-amino Oxazepam
Clozapine Oxycodone
Cocaine Paroxetine
Codeine Promethazine
Diazepam Propranolol
EDDP Quetiapine
EMDP Sertraline
Evo-a-acetylmethadol THC
Flunitrizepam THC-acid
Flunitrizepam, 7-amino Tramadol
Fluoxetine Tramadol-o-desmethyl
Fluoxetine, nor- Triazolam
Ketamine Venlafaxine
Ketobemidone Zaleplon
Lamotrigine Zolpidem
Lidocaine Zopiclone
Lorazepam Zuclopenthixol
Methadone
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parameters that provided the highest stable signal (Table III).
The source and desolvation temperatures were 120 and 4008C,
respectively. The calibration curves comprised the peak analyte
area/peak IS area versus concentration.
The AGP column was washed with 25% 2-propanol at 308C
for 30 min at the end of each series. The LC–MS-MS system
without the AGP column was washed with pure 2-propanol
after every 500 injections; this resulted in more stable chroma-
tography over time.
Results
Method optimization
The ACN precipitation resulted in the highest clarity of super-
natant, and ion suppression was very low when combined with
SPE. Therefore, we selected this procedure.
All of the examined SPE columns demonstrated good metha-
done recovery. The Strata-X-C column was chosen for further
development, because it provided the best EDDP recovery
(data not shown). Both the 80:20 v/v toluene–ethylacetate and
the 50:50 v/v ACN–H2O washing solutions reduced the analyte
recovery and had little effect on the presence of phospholipids.
Both ACN and MeOH efﬁciently removed phospholipids, and
washing with 1,800 mL was more effective than washing with
900 mL. Washing with ACN reduced the EDDP recovery, and
therefore MeOH was selected as the organic wash for the SPE
column. An additional wash with 0.1M HCl did not reduce
recovery.
When MeOH–NH3 was used for elution, both methadone
and EDDP were observed in the ﬁrst 100 mL, and they were
fully eluted after 300 and 700 mL, respectively (Figure 1).
When ACN–NH3 was applied, neither compound was observed
in the ﬁrst 100 mL, and both were fully eluted after 300 mL.
During the MeOH–NH3 elution, a large increase in phospholi-
pids was observed over the ﬁrst 500 mL; in contrast, with the
ACN–NH3 elution, only a weak increase was observed after the
ﬁrst 100 mL. We chose to use the ACN–NH3 elution, and we
decided not to collect the ﬁrst 100 mL (which made this a
small “wash step”); instead, we only collected the next 400 mL.
The necessity of adding formic acid to the eluate before
evaporation was evaluated based on the ﬁnal recovery of
methadone and EDDP. Without formic acid, EDDP was un-
stable, and the compound was almost completely lost when
the eluate was left overnight before evaporation. Adding 20 mL
of 2% formic acid to the collection tray before elution resulted
in stable recovery of the compounds (data not shown).
For LC, a slow gradient increase from 5 to 12% of 2-propanol
was necessary to ensure stable ionization. This slow increase
resulted in a slightly longer run time, but provided a more
stable signal for R-methadone, which eluted during the gradi-
ent step. A 20% 2-propanol step was included in the gradient
to clean the column before the next injection. The highest
recommended organic percentage (25%) was applied to the
column at the end of each run at 308C for 30 min; this ensured
good retention time stability and long column life. Retention
time varied slightly between runs, depending on the exact pH
of the ammonium acetate buffer; however, within each run,
variations in retention time did not exceed +0.1 min among
70 injections, which included 48 brain extracts.
Validation
The selectivity study did not reveal any interfering peaks in the
m/z tracks monitored for enantiomers of methadone and
EDDP. No ion suppression was observed for the mobile phase
or the extracts. A representative example is shown in Figure 2.
The matrix effects of the samples were nearly identical for
the IS and analytes. The respective matrix effects for
R-methadone and S-methadone were 5.8+0.5% and 4.3+0.8%
in brain, and 8.4+9.3% and 6.6+10.3% in blood. For R-EDDP
and S-EDDP, the respective matrix effects were 10.7+0.8%
and 11.4+0.6% in brain, and 28.8+10.0% and –9.6+11.2%
in blood.
The methadone extraction recoveries were 67 and 78% in
brain and blood, respectively. The EDDP extraction recovery
was, on average, 62% for both brain and blood. Due to the lack
of complete ACN supernatant transfer and the matrix effects,
in routine analyses, the total signal recoveries were, on average,
55% in brain and 53% in blood for EDDP, and 64% in brain and
62% in blood for methadone.
The linearity results are given in Table IV. Non-linearity was
observed for methadone above 1 mg/kg, but EDDP did not
exhibit non-linearity over the examined range. However, an
intercept setoff was observed for the two EDDP enantiomers,
due to low EDDP levels in the IS. Thus, a two-point calibration
line was used (0 and 0.5 mg/kg). Five of the calibrators exam-
ined were as a minimum between the ﬁnal LLOQ and HLOQ.
Accuracy and precision data are presented in Table V.
Precision is presented as the total relative standard deviation
(%RSD) over all 12 measurements; accuracy is based on the
theoretically calculated fortiﬁed values. The chosen criteria
included the maximum %RSD, set to 20% at LLOQ and 15% at
Table III
Chromatography and MS-MS Conditions of the Method*
Rt (min) Cone (V) Collision 1 (V) Transition 1 MRM Collision 2 (V) Transition 2 MRM Ion Ratio MRM2/MRM1
R-Methadone 12.32 26 14 310.1 . 265.1 26 310.1 . 105.1 2.98
R-Methadone-D3 12.25 25 15 313.15 . 268.1
S-Methadone 14.48 26 14 310.1 . 265.1 26 310.1 . 105.1 2.98
S-Methadone-D3 14.58 25 15 313.15 . 268.1
R-EDDP 8.63 45 30 278.1 . 234.1 24 278.1 . 249.15 2.08
R-EDDP-D3 8.58 43 30 281.1 . 234.1
S-EDDP 10.63 45 30 278.1 . 234.1 24 278.1 . 249.15 2.08
S-EDDP-D3 10.55 43 30 281.1 . 234.1
*Note: Positive ion mode was used.
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levels above LLOQ, and maximum accuracy, set to 80–120% at
LLOQ and 85–115% at levels above LLOQ. For brain tissue, a
%RSD up to 17% over LLOQ was acceptable at some levels due
to the complexity of the matrix. In brain tissue, the LLOQ was
0.005 mg/kg for the methadone enantiomers and 0.001 mg/kg
for the EDDP enantiomers. In blood, the LLOQ was 0.001 mg/L
for all analytes. Based on the non-linearity observed previously for
methadone enantiomers (linear up to 1 mg/kg, but low accuracy
at 2 mg/kg), the HLOQ was considered to be 1 mg/kg for both
methadone enantiomers. Samples with higher concentrations
were diluted and reanalyzed. The HLOQ for EDDP enantiomers
was 2 mg/kg in both matrices. The LOD was 0.0005 mg/kg in
blood and brain for all analytes (based on three times the standard
deviation at LOQ). Intermediate precision was observed for blood
and brain samples tested over 15 and 11 days, respectively.
Table VI presents precision measurements for the two QC levels,
0.005 and 0.25 mg/kg (6.8–15%). The ion ratio deviated less than
+15% at 0.0005 mg/kg for all compounds over the 12 precision
and accuracy measurements.
Stability of fortiﬁed blood samples was examined at high and
low levels. Over three thaw/freeze cycles, both methadone and
EDDP concentrations fell by 20–25%. In addition, the metabol-
ite, EDMP, was detected in the sample. Brain tissue extracts
from the ﬁrst day of the precision and accuracy experiments
were reanalyzed after seven days at 208C, 10 days at –208C, or
163 days at –208C. We found no relevant differences compared
to a fresh system control. Carry-over was examined by injecting
2 mg/L standards, followed by blank mobile phase. We
observed 0.01–0.03% carry-over for all four compounds.
Application
The described method was applied to authentic brain and
femoral blood samples. The sum of methadone enantiomer
concentrations was compared with achiral measurements from
68 femoral blood samples that had been completed earlier
using an accredited in-house method (33). A correlation of
R2 ¼ 0.93 was observed (Figure 3). When the results from
diluted samples (dilution factors between 2 and 10) were com-
pared to those from undiluted samples, a correlation of R2 ¼
0.996 was observed for the blood samples, and a correlation of
R2 ¼ 0.993 for the brain samples.
In 11 authentic cases, we compared concentrations of white
and grey brain matter, and the ratios of compound concentra-
tion in grey matter to that in white matter were 1.4+0.5 for
R-EDDP, 1.6+0.6 for S-EDDP, and 0.7+0.2 for both metha-
done enantiomers. White matter had to be diluted before ex-
traction, because otherwise, its consistency resulted in poor
precipitation. Therefore, grey matter alone was used in further
studies. Table VIIA shows brain and femoral blood measure-
ments from six authentic cases.
The same AGP column was used during method develop-
ment, validation and analysis of brain samples. The column
showed no sign of wear through approximately 1,000 brain
extract injections. However, the front column was changed
several times during this period. Chromatography was stable
among different columns bought from the same manufacturer.
Discussion
Several methods have been published for chiral determination
of methadone alone or in combination with EDDP and EDMP
in various neat sample types, including serum, plasma and
urine (9–13,17,18,20–23). Most methods applied liquid–liquid
extraction (9,11,12,14,15,18,20–23,29), and more recent
methods included LC–MS (10, 11, 16, 18, 20) or LC–MS-MS de-
tection (12–14,29). By quantifying the R-methadone and
S-methadone enantiomers separately, it is possible to perform a
toxicological interpretation of the active R-enantiomer alone.
Only very few publications contain data regarding the separate
Figure 1. Response of EDDP or methadone in collected volumes during elution with
5% 25% NH3 solution in methanol (MeOH–NH3) (A); 4% 25% NH3 solution in ACN
(ACN–NH3) (B); total signal for all peaks in 104 . 104 m/z chromatogram (C).
Volumes collected of the ACN–NH3 eluate in the final method are indicated with the
two black lines.
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enantiomers in more complex matrices, like whole blood and
tissue (21, 24, 29). In contrast, several achiral methods have
been published (25,26,33–36). Measurement in matrices other
than blood provides supplementary information that may be
valuable for interpreting drug levels (27, 28).
Precipitation and SPE
The removal of lipids from brain extracts was the primary focus
of the present method development. This necessitated thor-
ough examinations of the precipitation, SPE, washing and
Figure 2. Ion suppression examination of the quantification tracks for EDDP and methadone: mobile phase and brain extract injected during 1 mg/min EDDP (A); methadone
(B) compared to 0.1 mg/L injection.
Table V
Precision and Accuracy (n ¼ 12) Results from the Method Validation*
R-methadone S-methadone
Level %RSD Accuracy % %RSD Accuracy %
mg/kg Blood Brain Blood Brain Blood Brain Blood Brain
0.0005 (16) (111) (20) (114)
0.001 10.0 (19) 101 (79) 11.7 (22) 104 (72)
0.005 8.8 13.6 101 98 9.0 14.7 103 97
0.05 11.5 10.4 103 96 12.4 11.7 107 95
0.25 12.1 14.8 102 100 12.8 16.4 104 99
1 11.9 15.8 97 95 12.0 17.2 98 94
2 (11.0) (14.9) (87) (93) (11.7) (16.3) (88) (91)
R-EDDP S-EDDP
Level %RSD Accuracy % %RSD Accuracy %
mg/kg Blood Brain Blood Brain Blood Brain Blood Brain
0.0005 (24) (123) (24.7) (125)
0.001 12.6 20 106 84 11.2 19 109 83
0.005 11.0 7.8 99 99 10.5 8.7 100 99
0.05 13.5 5.0 101 96 11.8 5.9 102 96
0.25 12.7 9.0 100 99 12.4 9.6 101 99
1 14.3 10.1 99 97 13.5 10.8 100 97
2 12.6 9.5 95 101 11.9 10.5 95 101
*Note: Levels where values are given in parentheses are not included in the quantitative range.
Table IV
Linearity Properties for Methadone and EDDP in Blood and Brain*
Methadone EDDP
Blood Brain Blood Brain
Range LLOQ–HLOQ (mg/kg) 0.001–1 0.005–1 0.001–2 0.005–2
R2 0.997 0.985 0.997 0.980
Slope (R/S)† 42.4/42.1 57.0/56.5 43.9/44.0 47.7/47.2
Intercept† — — 0.012/0.012 0.012/0.012
*Note: No variation was observed between the R- and S-enantiomers.
†Slope and intercept given is the average found over five analytical runs.
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elution steps. Published works involving complex matrices
emphasized the necessity of good sample cleanup. Choo et al.
observed that precipitation of breast milk before SPE treatment
helped remove proteins and lipids and resulted in a more
stable SPE ﬂow (25). When precipitation is conducted, a loss in
recovery is expected, because analytes are captured in the
protein precipitates (21, 37). Here, this loss was an accepted
tradeoff for a cleaner ﬁnal extract. The addition of IS to the
samples before precipitation corrected for analyte loss during
this step. A comparison of quality among precipitation methods
was conducted on an achiral C18 column instead of the chiral
AGP column. The more robust C18 column allowed a 100%
organic phase that allowed chromatographic visualization of all
potential contaminants and impurities in the extracts. This
would not be possible on the AGP column, because a
maximum 25% organic phase is recommended, thus potential
contaminants trapped on the column would not be detected.
SPE has the advantages of a reduced sample volume require-
ment and the potential for automation. Bones et al. (38) thor-
oughly compared the extraction of compounds (including
methadone and EDDP) from water samples with Strata-X,
Strata-X-C and Strata-X-C-W columns. They achieved the best
recovery of methadone and EDDP with a Strata-X-C column at
pH 6 by eluting with 5% 25% NH3 in MeOH. The SPE recover-
ies for methadone (76%) and EDDP (63%) were comparable
with those observed in the present study, despite our use of
ACN–NH3 as the elution medium. The Strata-X-C column has
been used by others to extract methadone with EDDP and
EDMP from breast milk (25) and by the manufacturer to
extract these analytes from plasma. Those studies also noted
the feasibility of using a high percentage of organic solvent in
the wash step to ensure a high degree of cleanup without
analyte loss. SPE chromatography revealed that ACN–NH3 was
a better elution solvent than the MeOH–NH3 suggested by the
manufacturer and used by other groups (17, 25, 38). Eluting
with ACN–NH3 resulted in a cleaner ﬁnal extract; the eluted
phospholipids could be minimized signiﬁcantly by discarding
the ﬁrst 100 mL of the eluate, and collecting only slightly more
volume than the amount needed for maximum recovery of the
two analytes.
Chiral-LC–MS-MS
Other methods for the chiral separation of methadone and
EDDP on an AGP column have generally used ACN (10, 12, 19,
22, 29) or 2-propanol (14, 16, 17, 21) as the organic phase in
isocratic LC. Of the two, 2-propanol is cheaper and less
harmful, and a 2-propanol gradient can achieve full separation
of the enantiomers on the LC system after a relatively short
time compared with other chiral methods (15, 16, 22, 23, 29).
The ﬁnal 10 min of the gradient functions as a rinsing step, and
this might be excluded for examining neater samples (e.g.,
urine or plasma), which would result in an even shorter LC
run time. Overall, chromatography provided good selectivity,
with no detectable interfering compounds.
Validation
The presented method is suitable for routine analyses of
methadone and EDDP in brain and blood samples. Its quantita-
tive range extends well below the therapeutic methadone level
(0.05 mg/kg racemic) and into the highly toxic range. Because
this method requires low sample volumes, it is possible to
prepare samples in a compact 96-well setup. This results in a
short sample preparation time, due to the automation of
sample precipitation, extraction, evaporation and reconstitu-
tion. The selectivity of the method was thoroughly examined
with a wide range of common drugs, and no interference was
Figure 3. Comparison of total methadone concentration measured with the
presented method and in routine analysis (n ¼ 68).
Table VI
Intermediate Precision for Low QC and High QC Measured in Brain (N ¼ 11) and Blood (N ¼ 15)
R-methadone S-methadone
Level %RSD Accuracy % %RSD Accuracy %
mg/kg Blood Brain Blood Brain Blood Brain Blood Brain
0.005 11.7 15 98 96 9.9 15 96 98
0.25 10.9 6.8 96 97 11.3 6.8 95 98
R-EDDP S-EDDP
Level %RSD Accuracy % %RSD Accuracy %
mg/kg Blood Brain Blood Brain Blood Brain Blood Brain
0.0005 7.5 8.5 96 103 7.8 8.3 96 103
0.25 9.6 9.2 94 108 9.8 9.0 94 108
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observed for methadone or EDDP. The accuracy and %RSD for
the blood analysis were 95–109% and ,15%, respectively, at
all levels. In addition, a %RSD slightly greater than 15% was
accepted in brain samples at two levels of methadone (16% for
0.25 mg/kg and 17% for 1 mg/kg). The 0.25 mg/kg level was
examined over 11 days with a %RSD ,10% for all analytes, indi-
cating that the initial %RSD was slightly high and thus, it was
valid to accept the two .15%.values.
Because, in some cases, EDDP is present at very low concen-
trations, the low LLOQ (0.001 mg/kg in blood and brain
samples) of the method represents an advantage for pharmaco-
kinetic studies and other considerations, like distinguishing
between acute or chronic intoxication. In addition, diluting the
sample with buffer provided reliable results; thus, the HLOQ
can easily be extended.
Evaluating the effect of thawing and freezing is more rele-
vant for blood than for brain samples. Of the two matrices,
only blood is currently used for routine analyses, and therefore,
only blood is affected by freeze/thawing. In previous studies,
no degradation of plasma samples was observed over three and
ﬁve thaw/freeze cycles (10, 14). The degradation observed in
the present study may be explained by the complexity of the
whole blood samples. The loss of analytes observed over the
thaw/freeze cycles highlights the importance of avoiding
repeated thawing of samples.
The matrix effect showed very low variability for brain and
high variability for blood. This probably depends on the opti-
mization of extraction conditions. The use of an isotopic IS cor-
rects for the matrix effect; we found very good agreement
between methadone concentrations determined with this
method and those determined with our in-house accredited
method (Figure 3).
Wang et al. presented methadone enantiomer measurements
in brain tissue with achiral quantiﬁcation of EDDP (24). Their
method was developed for plasma and applied to different
mouse tissues to estimate the effects of P-glycoprotein on
methadone distribution (24). In comparison, our method
allowed chromatographic separation of both methadone and
EDDP enantiomers in less than half the run time, and the LLOQ
was 10 times lower than their LOD for both methadone and
EDDP (0.001 versus 0.01 mg/kg) with only one-ﬁfth of the
amount of sample. Our method was developed for routine ana-
lyses of both brain and whole blood samples. To our knowl-
edge, this is the ﬁrst published method to include a chiral
determination of methadone and EDDP in human brain tissue.
Application
The data presented from the six examined cases (Table VIIA)
showed large inter-individual variations in the brain/blood ratios.
The mean methadone brain/blood ratio (2.6 for both R and S)
and the large inter-individual variation were on the same order
as those reported by others (39–42). Only one publication has
been found that has an R/S-methadone ratio in whole blood of
1.46 (29), which is very close to the ratio observed in the
present study (median 1.70, Table VIIB). The R/S-methadone
ratio that we observed in brain tissue (median 1.67) was very
close to the value observed for blood, and it was consistent with
the R/S-methadone ratio of 1.5 determined by Wang et al. in
mouse brain (24). The R/S-EDDP ratio was previously character-
ized as ,1 in plasma (13) and 0.9 in whole blood (29). Those
values were consistent with our observed ratio of 0.70. We
observed a large inter-individual variation in the methadone/
EDDP ratio in blood among the 6 cases. Similar variation has
been noted by others (7, 8). These very limited preliminary
results indicated that the method provides reliable results.
Conclusion
A highly selective, sensitive, chiral method for determining
methadone and EDDP levels has been developed for routine
analysis of blood and brain tissue. Results observed in a prelim-
inary examination of authentic postmortem blood samples
were consistent with values published previously in the litera-
ture. To our knowledge, this is the ﬁrst published method for
the quantiﬁcation of methadone and EDDP enantiomers in
human brain tissue.
Table VIIB
Calculated R/S Ratios Based on Values Given in Table VIIA, with More Decimals than Given in
Table VIIA Used For Calculation.
R/S
Methadone EDDP
Case Brain Blood Brain Blood
1 1.20 1.12 0.71 0.67
2 1.14 1.18 0.67 0.59
3 1.58 1.43 0.62 0.70
4 2.25 2.38 0.65 0.70
5 1.76 1.96 0.71 0.88
6 1.87 2.00 1.06 1.10
Median 1.67 1.70 0.69 0.70
Table VIIA
Measured Methadone and EDDP Enantiomers in Postmortem Brain and Blood from Six Deceased Drug Addicts*
Case History Brain (mg/kg) Blood (mg/kg)
Case Age Sex R-Mtd S-Mtd R-EDDP S-EDDP R-Mtd S-Mtd R-EDDP S-EDDP
1 41 M 0.070 0.058 (0.0004) (0.0005) 0.051 0.046 0.003 0.005
2 45 M 0.165 0.145 0.001 0.002 0.092 0.078 0.014 0.024
3 59 M 0.523 0.331 0.008 0.013 0.148 0.104 0.026 0.037
4 56 M 1.617 0.717 0.030 0.046 0.652 0.273 0.105 0.149
5 57 F 2.515 1.427 0.023 0.032 1.026 0.523 0.160 0.182
6 42 M 4.559 2.435 0.050 0.047 1.173 0.587 0.137 0.124
*Note: The samples are ordered from lowest to highest blood R-methadone concentration. Concentrations given in parenthesis are below LOQ. Mtd: methadone.
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